SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: NeuroInvestment who wrote (14504)12/4/2004 11:09:00 PM
From: Archie Meeties  Read Replies (2) | Respond to of 52153
 
NI,

As I understand it, the risk of agranulocytosis in clozaril is conferred by a defect in an oxidative step. If acp-104 lite follows another metabolic pathway, then this side effect may be avoided. That alone would be enough take the lions share of the atypical market IMO, let alone the other issues you brought up.



To: NeuroInvestment who wrote (14504)12/5/2004 4:45:44 PM
From: Biomaven  Respond to of 52153
 
ACP-104N

This is desmethylclozapine. Not sure if SEPR was asleep at the wheel here or not. They have a slew of patents surrounding metabolites of all the other atypicals, but somehow they seemed to have missed this one.

I've never looked at Acadia - thanks Rick and Harry for pointing me in their direction.

Peter


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News